Background. The synthetic prostacyclin analogues have been proposed to protect against cyclosporin A (CsA) nephrotoxicity. The present study investigated the effect of infusion of the prostacyclin analogue iloprost on the acute CsA-induced renal hypoperfusion and hypofiltration in stable renal-transplant recipients. Methods. The study included 10 stable renal-transplant recipients with good graft function (s-creatinine 90-170 umol/1). Renal function and the acute renal haemodynamic and tubular response to an oral CsAdose (Sandimmun Neoral, Smgkg" 1 ) were investigated with an infusion of iloprost (1 ng-kg~1-mkf
Introduction
Cyclosporin A (CsA)-induced renal dysfunction remains a concern in organ transplantation. One pattern of CsA nephrotoxicity is a reversible vasoconstriction and a decrease in the glomerular filtration rate (GFR) [1] . Even in stable renal transplant recipients, daily renal hypoperfusion occurs in relation to the peak CsA blood concentration [2, 3] . This CsA-induced renal vasoconstriction is mediated or modulated by various endogenous vasoconstrictors and vasodilators [4, 5] , including prostaglandins. Thus, in vitro studies and studies in experimental animals have demonstrated that CsA affects the synthesis of renal cyclo-oxygenase metabolites, with a reduction in vasodilatory prostacyclin (PGI 2 ) and prostaglandin E 2 (PGE 2 ), and an increase in the potent vasoconstrictor thromboxane [5, 6] . The glomerular and renal endothelial synthesis of the vasodilating prostaglandins is important in maintaining GFR, at least under experimental and clinical conditions with an increase in renal vasoconstrictive agonists, such as noradrenaline and angiotensin II [7] . A CsA-induced reduction in the synthesis of vasodilatory prostaglandins may therefore reduce renal haemodynamic capacity to compensate for endogenous vasoconstrictive stimuli. In accordance with this, some studies in experimental animals have found that treatment with synthetic PGI 2 analogues reduces CsA nephrotoxicity [8, 9] . Besides the effect of the synthetic PGI 2 analogues on CsA nephrotoxicity, the PGI 2 analogues (iloprost, 15 AU81 and OP-41483) have also been reported to enhance the immunosuppresive effect of CsA in experimental animals [9] [10] [11] .
Iloprost is a stable carbaprostacyclin analogue, which in experimental animals seems to have the same haemodynamic and humoral effects as naturally occurring PGI 2 , and which has been demonstrated to cause renal and systemic vasodilatation in humans [12, 13] . To our knowledge, the present study is the first to investigate whether the vasodilating abilities of infusion of a PGI 2 analogue have any beneficial effects on CsAinduced renal hypoperfusion and hypofiltration in renal transplant recipients.
EfTects of the prostacyclin analogue iloprost on cyclosporin-induced renal hypoperfusion

Subjects and methods
Experimental protocol (Figure 1 ) 341 
Subjects
The study was approved by the Ethical Committee of Copenhagen County, and all subjects entered the study after having given written informed consent. Eleven healthy renal transplant recipients, with a stable good renal graft function for more than 6 months (s-creatinine ^ 170 umoll" 1 ), were included in the study. No patients had any sign of chronic renal graft rejection, or had experienced any acute rejection episodes since the initial period after transplantation. Demographic and clinical data are shown in Table 1 . The patients all received immunosuppressive medication including prednisone, azathioprine, and low-dose CsA. Patients receiving dihydropyridine calcium antagonists were not included in the study, because of the well-known effects of these drugs on renal haemodynamics [3] . All medications remained unchanged in the study period, during which the patients were further instructed not to take non-steroidal antiinflammatory drugs, or to change their diet or level of physical activity. Data are mean and range in parenthesis, or number of subjects.
All patients were investigated twice in a randomized singleblind fashion with either placebo or iloprost infusion. The renal clearance protocol was identical on the 2 study days, which were separated by at least 1 week. To maintain approximately the same sodium and protein load, the patients had to keep to an individualized diet by the use of a diary, starting 3 days before each study. In the same period, exhaustive exercise and alcohol intake was prohibited. The patients were studied in the morning after an overnight fast and abstained from smoking and caffeine-containing beverages until completion of the renal clearance investigation. Lithium carbonate (Li 2 CO 3 ; 300 mg, 8.1 mmol) was given at 8.00 p.m. the night before the clearance study. The renal clearance study consisted of seven consecutive renal clearance periods of 30 min each; two baseline periods, three periods with iloprost or placebo infusion, and two recovery periods. Water diuresis was induced by an initial oral water load of 500 ml at 7.00 a.m., followed by 250 ml every 30 min. The patients were investigated in a supine resting position except for briefly standing when voiding every 30 min. At 8.30 a.m., an oral CsA-dose (Sandimmun Neoral) of 3 mg kg ~' body weight was given. Renal clearance measurements started at 10 a.m., l^h after CsA intake. Infusion of iloprost diluted in isotonic saline was given in a single-blind design, with a starting-dose of 0.5 ng-min"'-kg~1 body weight for 30 min, increased to 1 ng-min"'-kg~1 body weight for the last hour. Placebo infusion was given as isotonic saline using the same infusion speed. Eight of the patients accepted participation in an additional control renal clearance study without CsA intake or iloprost/placebo infusion.
Effective renal plasma flow (ERPF) and GFR were measured by a constant infusion technique using 13 M-hippuran and 99m Tc-diethylene-triamine-penta-acetate (DTPA) in a total dose of 3.6 MBq and 27.0 MBq respectively. After an equilibration period of at least l^h, renal clearances of 131 Ihippuran, 99m Tc-DTPA, lithium (C Li ) and sodium (C Nn ) were calculated from the urinary excretion rates and plasma samples drawn in the middle of each period. C u was used as an index of proximal tubular outflow of sodium and water. Plasma for analysis of renin, aldosterone, adrenaline and noradrenaline were drawn in the middle of the last baseline period and in the middle of the last period with iloprost or placebo infusion. Tc-DTPA in the first two baseline periods was considered as due to incomplete bladder emptying. However, no patients fell within this exclusion criterion.
Analytical methods
Activities of 131 I-hippuran and 99m
Tc-DTPA were determined in a well scintillation counter (Cobra 5003; Packard Instrument Company, Meriden, CT, USA). Plasma sodium was measured with a Technicon RA 1000 and urinary sodium with a Technicon RA-XT (Tarrytown, NY, USA). Lithium in plasma and urine was measured using an atomic absorption spectrophotometer (Model 403; Perkin Elmer, Norwalk, CT, USA). Active renin was measured by a two-site, twomonoclonal antibody immunoradiometric assay with plastic beads for solid phase (Nichols Institute, San Juan Capistrano, CA, USA). The bound antibody was directed against the active site on renin, while the other antibody was iodinated. The detection limit was 2 mU-1" 1 , the intra-assay coefficient of variation was 4% and the interassay coefficient of variation was 5%. Aldosterone was measured by immunoassay in unextracted serum (Diagnostic Products Corporation, Los Angeles, CA, USA). The detection limit was 41 pmol I" 1 , the intra-assay coefficient of variation was 10% and the interassay coefficient of variation was 15%. Plasma adrenaline and noradrenaline were determined by a radioenzymatic method as previously described [14] . The intra-assay coefficient of variation for adrenaline and noradrenaline was 8% and 6% respectively, and the interassay coefficient of variation was 11% and 7% respectively. Wholeblood trough levels of CsA, including its metabolites, were measured by fluorescence polarization immunoassay using an Abbott TDxFLx (Abbott Laboratories, Chicago, IL, USA).
Calculations
Filtration fraction (FF) was calculated as GFR/ERPF. Absolute proximal tubular reabsorption of sodium and water (APR) was calculated as GFR-C Li . Fractional proximal tubular reabsorption (PFR) was calculated as l-(C Li /GFR). Absolute distal tubular reabsorption of sodium (ADR Na ) was calculated as (C Li -C Na )P Na , where P Na is plasma concentration of sodium. Fractional distal tubular reabsorption of sodium (FDR Na ) was calculated as (C Li -C Na )/C Li . Mean arterial blood pressure (MAP) was calculated as the distal blood pressure plus one-third of the pulse pressure. In each patient the blood concentration-time curve of CsA was registered and the trough level (C min ), the maximum concentration ( C J and the time from CsA-administration to C ,( tmax) were determined, and the area under the concentrationtime curve (AUC) for the 4 | h after CsA-ingestion was calculated by trapezoidal rules.
Statistics
The data were analysed in two steps with analysis of variance for repeated measures (ANOVA). One ANOVA was done using all 3 study days as trial factor, and the other using only the 2 days with CsA intake and infusion as trial factor, and further analysing the control day separately. If the last analysis demonstrated significant time-induced differences between the 2 days with CsA intake and infusion, data were further analysed by paired /-test. Because the plasma renin and aldosterone had skewed distributions, logarithmic transformations were done before statistical testing. The nullhypothesis was rejected when /'<0.05. Unless otherwise indicated, data are presented as means+ SEM. All statistical data analysis was done using the statistical software package Systat ver. 5 (Systat Inc., Evanston, IL, USA).
Results
One patient had transient discomfort, hypotension and bradycardia at the end of the iloprost infusion and was excluded from the study before data analysis. Eight of the included patients developed a slight headache and one patient had facial flushing at the end of iloprost infusion. Further, two patients reported fatigue after the iloprost infusion was stopped. During placebo infusion one patient had a slight headache, but no patients reported symptoms on the day without CsA intake and without infusion.
The bioavailability of CsA was the same on the 2 days with CsA intake, as reflected by comparable C min , C max , t max , and AUC ( Table 2 ). The C min on the control-day was comparable with the two study days with CsA-ingestion ( Table 2) .
Iloprost infusion decreased blood pressure and increased heart rate significantly ( Figure 2 ). There was a tendency towards an increase in blood pressure without iloprost, which only became significant at end of the control day and in the last recovery period on the day with iloprost-infusion ( Figure 2 ). There was no change in heart rate on the control day and on the day with CsA intake and placebo infusion (Figure 2 ).
Renal haemodynamics
In Tables 3 and 4 , data are presented as baseline, infusion, and recovery, which represents the mean of the renal clearance periods 1+2, 4 + 5 and 6 + 7 respectively. ANOVA revealed a significant difference in the overall time-response in ERPF, GFR and FF between the 3 investigation days (/ > <0.05, / ) <0.05 Cmin, CsA trough blood concentration; C mM , peak CsA blood concentration; t^^, the time to peak CsA concentration; AUC, the area under the concentration-time curve. Data are means+ SEM.
Effects of the prostacydin analogue iloprost on cyclosporin-induced renal hypoperfusion Figure 3 ). CsA-ingestion decreased ERPF and GFR significantly with a maximum decline towards the end of the clearance study (Table 3 and Figure 3 ). Iloprost-infusion abolished the CsA-induced decrease in ERPF, but had no effect on the CsA-induced decrease in GFR, leading to a highly significant decline in FF (Table 3 and Figure 3 ). ERPF decreased and FF increased significantly after stopping the iloprost-infusion (Table 3 and Figure 3 ). There were no significant changes in ERPF or GFR during the control study (without CsA intake and without infusion), although a minor increase in filtration fraction was found (Table 3) . Renal tubular function ANOVA revealed a significant difference in the overall time-response in C Li , ADR Na , and urinary flow rate between all 3 investigation days (P<0.05, P<0.05 and / > <0.001 respectively; Figure 4) , and there tended to be a significant difference in the time-response in PFR between the three days (P=0.07; Figure 4 ). There was no significant difference in the overall absolute level of C Li , APR, PFR, ADR Na , FDR Na , C Na , or urinary flow rate at the 3 study days (Table 4 ). There was no difference in the time-response at the 2 days with CsAingestion and iloprost or placebo infusion in any of the investigated tubular parameters (C Li , APR, PFR, ADR Na , FDR Na , C Na and urinary flow rate). There was an overall decrease in C Li on the days with CsAingestion (P<0.001), whereas there was no significant change in C Li on the control day ( Figure 4 and Table 4 ). APR decreased significantly with no difference between the 3 study days (P< 0.001; Figure 4 and Time (hrs) Fig. 3 . The effect of CsA intake and iloprost infusion on effective renal plasma flow (ERPF), glomerular filtration rate (GFR), and filtration fraction ( F F ) . For statistics see text and Table 3 . (P<0.05), whereas there was no significant change on the day without CsA intake ( Figure 4 and Table 4 ). The decrease in the proximal tubular outflow was compensated in a load-dependent way by the distal tubule, where ADR Na decreased highly significantly on the days with CsA intake (P<0.001), and remained without significant changes on the control-day ( Figure 4 and Table 4 ). This resulted in a comparable FDR Na and C Na on the 3 study days, with no timeeffect during the investigation (Table 4 ). The urinary flow rate decreased significantly on the 2 days with CsA intake (P < 0.001), and remained unchanged on the control day without CsA (Table 4) .
Hormones
ANOVA demonstrated an overall time-induced decrease in plasma renin with no significant difference between the 3 study days (Table 5) . Iloprost infusion reduced plasrha-aldosterone and increased plasmaadrenaline significantly, whereas there was no significant changes in these parameters during the 2 study days without iloprost (Table 5 ). There were no significant changes in plasma noradrenaline on the three study days (Table 5 ). 
Discussion
The present study is the first to report on the effect of a prostacyclin analogue on CsA-induced changes in renal haemodynamics in renal transplant recipients. Such patients, over several years of stable renal function, are subject to daily transient CsA-induced renal hypoperfusion and reduction in GFR [2, 3] . Thus, in the present study in renal transplant recipients who had all been transplanted for more than 6 months, an oral CsA-dose of 3 mgkg" 1 had an decreasing effect on both ERPF and GFR with a maximum decrease towards the end of the study, 5 h after CsA-ingestion and approximately 31 h after the peak CsA blood concentration. Whether these daily episodes of renal hypoperfusion play a role in the development of the histological changes of chronic CsA nephrotoxicity remains unclear.
Infusion of iloprost had no effect on this CsAinduced decrease in GFR, even though iloprost abolished the decrease in ERPF. An effect of iloprost on the renal tubular excretion of 131 I-hippuran cannot be excluded. The concomitant decrease in the arterial blood pressure indicates that the vasodilating ability of iloprost is a systemic phenomenon, which most probably also affects the renal arteries in accordance with the higher ERPF during iloprost infusion. To our knowledge, the impact of infusion of a PGI 2 analogue has not previous been investigated in CsA-treated subjects, but studies in patients with essential hypertension and thrombangiitis obliterans have likewise demonstrated systemic [12, 13] and renal vasodilatation [13] by infusion of iloprost in the same dose as the present study, but have contrary to our findings also demonstrated a large increase in GFR [12, 13] , and a significant increase in the filtration fraction [13] . More comparable with the present results is the study of Natov et al., who investigated the effect of PGI 2 -infusion in normal volunteers, and demonstrated a decrease in arterial blood pressure, an increase in renal plasma flow, with no change in GFR, and a decrease in filtration fraction [15] . It seems paradoxical that iloprost should abolish CsA-induced vasoconstriction without any impact on the decline in GFR. However, the effect of CsA on renal haemodynamic is mainly a constriction of the afferent arteriole [16] , whereas PGI 2 has been demonstrated to dilate both afferent and efferent arterioles [17] . Thus a possible explanation seems to be that infusion of iloprost during CsAinduced vasoconstriction mainly dilates the efferent arteriole, with only a minor effect on the constricted afferent arteriole, which also might explain the limited renal plasma flow response, when compared to the study of Arzelli et al. [13] .
The mechanism of the CsA-induced effect on renal haemodynamics is complex, and evidence does exist of an activation of several intrarenal vasoconstriction agonists, such as angiotensin II, endothelin, thromboxane A 2 , and platelet-activating factor [4, 18] . Data also implicate the participation of the sympathetic nervous system in CsA-induced vasoconstriction [19] . Beside its effect on the endogenous vasoconstrictors, CsA also decreases the synthesis of the intrarenal vasodilating cyclo-oxygenase metabolites. In vitro studies have shown a CsA-induced concentration-dependent decrease in PGI 2 and PGE 2 production from renal vascular endothelium [20] , mesangial cells [6, 21] and isolated glomeruli [21] . CsA also blunts the vasoconstrictor-induced synthesis of vasodilatory prostaglandins from glomerular and mesangial cells [21] . Renal cortical PGI 2 undergoes to some extent urinary excretion in form of its stable renal metabolite 6-keto prostaglandin F lot (6-keto PGF lct ). Data from studies investigating the impact of CsA on the urinary excretion of 6-keto PGF lot , however, are conflicting, demonstrating both unchanged, increased, and decreased excretion rates [22] [23] [24] .
Contrary to our findings, some experimental studies have found a beneficial effect of prostacyclin analogues on CsA-induced nephrotoxicity. A study in rabbits has demonstrated, that concomitant treatment with CsA and the synthetic PGI 2 analogue 15 AU81 abolishes the CsA-induced rise in serum-creatinine [8] . The PGI 2 analogue OP-41483 has been found to protect against CsA-induced renal histological changes in rats [9] . In glomeruli isolated from a human kidney, the CsAinduced decrease in the glomerular area was reversed by both pre-and post-treatment with iloprost [25] . By contrast, Dieperink et al. demonstrated no effect on the renal clearance of inulin of acute prostacylininfusion in rats with established CsA nephrotoxicity [26] .
It would have been expected that the iloprostinduced decrease in arterial blood pressure in the present study would have caused a reflex activation of the sympathetic nervous system, as actually suggested by the increase in HR and plasma adrenaline. Plasma noradrenaline, though, remained unchanged during iloprost infusion, contrary to the rise found in another human study [13] . Interestingly, PGI 2 has in vitro been demonstrated to inhibit sympathetic neurotransmission [27] , which could explain the lack of increase in plasma noradrenaline. Plasma renin fell on time during all three study days, and was not influenced by CsA or iloprost. Iloprost caused a decrease in plasma aldosterone; the mechanism of this is uncertain.
Proximal tubular function was investigated using the lithium-clearance method. The main assumption underlying this method as a non-invasive tool for assessing proximal tubular outflow is that filtered lithium is reabsorbed in the proximal tubule in the same proportion as sodium and water, whereas no lithium is reabsorbed in more distal nephron segments [28] . The lithium-clearance method is the best-known method to estimate renal tubular function in humans. However, results achieved by the lithium-clearance method have to be interpreted with caution when manipulating the prostaglandins, as inhibition of the cyclo-oxygenase by indomethacin have been shown to induce lithium reabsorption in the descending limb of the loop of Henle [29] . In the present study, however, no effect of iloprost infusion on lithium clearance was seen. CsA intake caused an acute decrease in the proximal tubular outflow, without affecting the sodium excretion. This effect of CsA on proximal tubular outflow is in agreement with previous results in rats, normal volunteers, and renal-transplant recipients, also using the lithium-clearance method [2, 30] . Although a direct effect of CsA on the tubular handling of sodium and water cannot be excluded, the almost parallel changes in C Li and GFR, and the comparable decrease in absolute proximal tubular reabsorption with and without CsA intake suggest that the decreased proximal tubular outflow is secondary to the CsA-induced changes in renal haemodynamics. CsA further caused a decline in urinary flow rate, which is most probably also secondary to the CsA-induced decreases in GFR and C Li . The unchanged sodium excretion, despite the considerable CsA-induced decrease in C Li , is secondary to a compensatory load-dependent decrease in distal tubular sodium reabsorption. Contrary to earlier studies where both iloprost and PGI 2 infusion has been demonstrated to have a natriuretic effect in humans [13, 15] , infusion of iloprost in the present study caused no changes in neither proximal or distal tubular function or in the natriuresis.
In conclusion, acute infusion of the PGI 2 analogue iloprost causes systemic and renal vasodilatation, as reflected by the reduction in arterial blood pressure and the abolishing of CsA-induced decrease in ERPF. However, the unchanged CsA-induced decreases in GFR and C Li during iloprost, suggest that acute iloprost-infusion has no effect on the acute nephrotoxicity of CsA in stable renal transplant recipients. Further studies are needed to define more clearly the role of the PGI 2 analogues in renal transplantation.
